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Abstract
Translational research conducted in academic health centers is confounded by the organizational
structure in which the work is performed. Investigators must obtain research funding and
appropriate recognition as a part of a research team in a not-for-profit environment which has
more readily rewarded basic work, and individual accomplishments. What results is a unique form
of conflict of interest, best understood by relating the basic principles underlying the not-for-profit
form to the conduct of translational research in the AHC setting.
Introduction
In his classic article entitled "On the Folly of Rewarding A
while Hoping for B", Kerr outlines a common phenome-
non in organizational management and behavior [1].
Employees receive explicit or implicit incentives (rewards)
to carry out one set of activities (A), while the organiza-
tion hopes that the same employees will also or instead
carry out a different set of activities (B). Conflict of inter-
est, not of the conventional type [2], is created between
what is rewarded and what is desired. This situation often
helps to explain the dichotomy between desired and
actual results. Kerr cites teaching in higher educational set-
tings as a prime example. Faculty are expected by the
organization to be devoted and excellent teachers, yet are
rewarded for endeavors other than teaching.
The premise of this article is that the same dichotomy
operates for translational research in AHC. The dichot-
omy emanates largely from the fact that AHC translational
research is typically conducted in the not-for-profit (NPO)
setting [3-7]. The dearth of physician-scientists working at
the translational interface is one consequence.
Forces Promoting the Not-for-Profit Form
In her book, "Strategic Management for Nonprofit Organ-
izations", Sharon Oster suggests three forces which pro-
mote the existence of the not-for-profit form [3]. A
paramount consideration is contract failure. Many if not
most NPO produce goods or services which are difficult to
evaluate in terms of quality. Under these circumstances, it
is both problematic and inadvisable to write or enforce a
contract between the provider and the stakeholders/con-
sumer/buyer. Instead, provision of services must be based
on trust between these two entities. This is the most direct
manifestation of public trust. A second force promoting
NPO is public failure, typically meaning that the govern-
ment cannot or will not provide the service, even though
the service is considered a public good. The last feature is
worker sorting. Individuals are attracted to work for NPO
based on the altruistic mission of the organization.
Employees often serve as volunteers or at compensation
levels below the market, if compared with for profit enter-
prises.
These three forces are inextricably linked to the most com-
monly appreciated feature of NPO: the non-distribution
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constraint, which in turn is linked to the special tax status.
The non-distribution constraint states that "any financial
surplus generated by operations cannot be distributed to
those in control of the operation", which includes the
stakeholders (in theory the public) and the employees of
the NPO. While this does not preclude NPO from having
positive cash flows, increasing net assets, or growing bal-
ances in endowment accounts, funds from these accounts
cannot be proportionately distributed in the form of
bonuses, or other direct benefits.
To what extent do non-profit Academic Health Centers
(AHC) conform to these criteria and to what extent do
they diverge? Answers to this question vary for the clinical,
educational, and research missions. This article will not
address the former two areas, and will approach only a
subset of the latter – basic and disease-oriented research
(as defined by Goldstein and Brown [8]), with a particular
focus on translational research. Patient-oriented research,
and specifically therapeutic trials, are best considered
under other paradigms.
Mission Statements and Research in AHC
How can the goal of the research mission within AHC best
be summarized? For most NPO, the mission statement
represents the most succinct and important expression of
the mission. A review of web sites for more than 100 AHC
revealed that only 1 in 5 had readily accessible and explicit
institutional mission statements. From these mission
statements, the statement referable to research was evalu-
ated. More explicit vision statements accompanied the
mission statements in some cases. A nearly constant
theme was that research should be translated into advan-
tage for human health. While this informal survey sug-
gests that AHC should be more attentive to explicit
statements of mission and vision, it also demonstrates the
expected and hoped for mandate that translational inves-
tigation be the goal of research in the not-for-profit AHC
setting.
Translational Research and Contract Failure in AHC
If the research mission of AHC is to make basic discoveries
which are translated into advantage for maintaining or
improving human health, does contract failure exist for
the translational research mission? Stakeholders (the pub-
lic) cannot easily judge the quality of scientific research
conducted by individual investigators, nor can they read-
ily determine the likelihood that advances will be trans-
lated into new diagnostics, therapeutics or preventative
strategies. By these criteria, the conditions for contract fail-
ure are met.
Given the existence of contract failure, to what extent does
the non-profit form provide reassurances that individual
investigators will neither provide a sub-standard product,
nor work towards goals which are not mission-based.?
With regard to the first issue, the guarantees for quality are
strict, since investigators are scrutinized by their peers for
the quality of the research conducted.
With regard to the second issue, the answer is much more
ambiguous when considering research funded through
the National Institutes of Health or other federal sources
(Department of Veteran's Affairs, Department of
Defense). There is a widely recognized tendency for review
groups to fund well written applications for which the
hypothesis being addressed is important, the preliminary
data are compelling, but most importantly, the proposed
experiments are likely to be successful and can be com-
pleted in the time frame of the award (personal observa-
tion). Direct applicability to human health may be
discussed, but rarely is used as an essential criteria in the
funding decision. Highly creative approaches, which the
investigator believes provide the best chance for making a
real impact for human health, will typically not be funded
without substantial preliminary data to indicate that they
will be successful. The complexities of conducting transla-
tional research, including insuring sufficient access to
patients and volunteers, meeting regulatory challenges,
conducting research in an only partially controlled set-
ting, and dealing with expensive infrastructure, all pre-
clude preparation of applications which have the
crispness and apparent sophistication of more basic pro-
posals. Similarly, extremely applied experiments, which
the scientist believes will most rapidly translate into an
advantage for human health, are often poorly received
because they are not considered sufficiently innovative.
(Of note, in the for-profit arena, these latter constraints
are minimized, given the imperative to establish marketa-
ble products). While funding agencies and AHC are vocal
advocates of translational research, reward systems are
structured to support less risky basic activities. Kerr is at
work.
These contentions cannot be readily proved or disproved,
because there is no set of uniform criteria by which to
make these judgments. The most relevant data comes
from comparison of NIH funding success rates for clinical
vs. non-clinical research. Two analyses [9,10], spanning
an era (1997–2004) where substantial emphasis was
placed on funding clinical research, revealed substantially
higher success rates for non-clinical than for clinical appli-
cations. More general perspectives reach the same conclu-
sion [11-13] Some of the above assertions are recognized
by the National Institutes of Health (NIH). As stated in
the description of high risk research in the NIH Roadmap
http://nihroadmap.nih.gov, "the NIH peer-review process
is oriented to fund so-called 'low-risk' proposals that
advance well-established areas of science. This leaves
many more speculative, or 'high-risk', proposals withoutJournal of Translational Medicine 2005, 3:19 http://www.translational-medicine.com/content/3/1/19
Page 3 of 5
(page number not for citation purposes)
an obvious mechanism of NIH support". One proposed
solution is the Directors Pioneer award http://nihroad
map.nih.gov/highrisk/initiatives/pioneer. The Pioneer
award provides up to $500,000 per year of direct costs for
5 years for investigators to explore ideas that are consid-
ered risky at their inception, yet for which strong prelimi-
nary data is lacking.
In contrast to the mandate for funding the Pioneer award,
the usually unstated "logic" of review groups for more
common funding mechanisms (e.g. R01) is different. The
assumption is made that allocating funds towards "safer"
projects, even when quite basic and without direct con-
nection to human disease, is ultimately the best way to
accomplish the mission, since it is probable that those dis-
coveries will ultimately contribute directly or indirectly to
more applied solutions.
Irrespective of whether this "logic" is or can ultimately be
validated, the premise of this manuscript is that it creates
a conflict of interest for translationally-oriented investiga-
tors. This conflict is typified in published papers and in
applications for research funding. It is commonplace for
the introduction and discussion/conclusion of grant
applications and manuscripts to make reference to the rel-
evance of the work for advancing human health. While
often done quite tangentially, this addresses the mission
of central importance to the public and arguably to the
AHC. If the author were to state explicitly that the likeli-
hood was extremely low that the proposed or completed
research would ultimately have any significant relevance
to human health (or would even be cited by other
authors), the application or manuscript would be seri-
ously compromised. In contrast, throughout the remain-
der of the application or manuscript (and hence in the
work itself), the investigator is compelled to focus on a
"mission" which is different – convincing fellow scientists
that the work is valid, irrespective of its relationship to the
broader mission of importance to the public. If instead,
the requirement at each step of the work was to make the
connection to human disease, the form of the experi-
ments would be often need to be altered in a fashion pre-
cluding the rigorous proof expected of high level scientific
investigation.
In the for-profit arena, by contrast, a focus on product
development with direct applicability to human health
necessarily dominates the investigative and development
process. Funding decisions are made internally. Prepara-
tion of peer-reviewed manuscripts is not an expected end-
goal of much of the investigation. Research form follows
desired organizational outcome more directly.
Translational Research and Public Failure in AHC
Does public failure exist for the translational research mis-
sion of AHC?
Leaving aside the legitimate debate as to whether advance-
ments in biomedical research in AHC are public goods, it
is a reasonable assumption that government cannot or
will not directly provide the vast array of biomedical
advances desired by the public. What is and what should
be the linkage between government and NPO in address-
ing this public failure? NPO often serve as a mechanism
for delivery of public services, in partnership with the gov-
ernment. In these situations (for example education,
transportation, environment), the government establishes
the services to be provided, and contracts with NPO to
provide those services.
Is this model applicable to biomedical research? In some
respects yes, but in many respects no. By far the largest
provider of funds for biomedical research in the United
States is the federal government, through the National
Institutes of Health. Who determines the criteria for pro-
viding the funds to the investigators, and what is the role
of government in insuring that there is an applied outlet
for the work [14]? The substantive scientific conditions,
which are the dominant consideration in determining the
likelihood of funding success, are established by the
investigators themselves, in the form of study sections and
review groups. These panels typically consist of investiga-
tors who have obtained NIH funding, usually in a some-
what related area, and who will generally apply for
additional NIH grant support in the future. In other
words, the grant is effectively awarded by the investigators
for the investigators, a notion far quite far astray from the
concept of public failure. No matter how supportive the
investigators may be of the government's overarching
goal, it is both human nature and part of one's training to
support "good science" (the kind of science they consider
themselves to do and to be rewarded for) over other fac-
tors. While the administrative conditions for the award
are set by the NIH, while budget allocations to individual
institutes or for particular initiatives do influence the
scope of the funded research, and while NIH program
officers have some discretion in insuring that grant awards
fulfill program goals, it is not even clear that budget allo-
cations faithfully match the burden of disease or govern-
ment intent [15-17].
These considerations are not meant to call into question
the rigor or validity of the review process, both of which
are held in high regard. Similarly, it remains the case that
the public recognizes the value of basic research, tempo-
rizing the extent of "public failure". Nonetheless, this per-
spective indicates that the hope for more and better
translational research is not faithfully aligned with theJournal of Translational Medicine 2005, 3:19 http://www.translational-medicine.com/content/3/1/19
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reward systems for most investigators. Based on the con-
siderations discussed above with regard to contract fail-
ure, it illustrates the potential conflict of interest between
the government and the public on the one hand, and the
government and the academic research community on the
other [14,18,19].
Translational Research and Worker Sorting in AHC
The pure concept of worker sorting suggests that biomed-
ical investigators work in AHC based on the organiza-
tional mission, and at some personal sacrifice, at least
financially. Is this formulation largely correct for the
translational research enterprise? Only partially.
Investigators wishing to establish an independent career
in research will nearly always opt to do so in AHC. The
attraction of doing so is not primarily the mission of the
organization, but rather the freedom of choice and the
breadth of opportunities which are provided to excel. This
is particularly true for bona fide translational research,
which is most easily conducted in the environment of an
AHC. Such opportunities, particularly for more junior
investigators, are simply not present in for-profit research
enterprises. In AHC, investigators strive to gain both rec-
ognition and support, for purposes of career advancement
and career stability. If such individuals respond to a mis-
sion statement at all, it is likely to be to the professional
organization/s of which they are members or occasionally
to a much broader mission statement which transcends
the institution. Investigators can even be likened to mini-
religious organizations, with a fervent zeal for their own
research which dominates other considerations [20]. The
institutional mission and organizational structure of the
AHC may even conflict with the individual mission state-
ment of the investigator, the latter of which often pro-
motes and condone individual pursuits but may or may
not be aligned with those of the organization [21]. At the
same time, the rewards to the investigator for conducting
translational research transcend some of these considera-
tions, and include improved patient recruitment, with
attendant increases in patient volume and clinical
income, increased personal recognition, and funds from
licensing agreements for intellectual property.
Programmatic and team-based investigation is increas-
ingly recognized as the most rapid and efficient structure
for scientific progress for many if not most questions – i.e.
to accomplish the research mission. In the for-profit-set-
ting, rewards can be readily distributed based on the per-
formance of the organization, and/or of individual teams
within the organization. In AHC, academic promotion,
research funding and professional recognition are far
more readily achieved from an individual standpoint.
Once again leaving aside the cogent arguments support-
ing both sides of this dilemma, individual accomplish-
ment is most readily rewarded, while funding agencies,
scientific organizations, AHC and the public hope that
team-based research will predominate.
There is a growing body of literature describing the
impediments to interdisciplinary research (IDR) in AHC,
and suggesting strategies to remove those impediments
[22]. Based on a survey of over 300 respondents, the five
most important recommendations for institutions to
facilitate IDR were a.) fostering a collaborative environ-
ment, b.) providing faculty incentives and organizing hir-
ing policies and tenure processes to support IDR, c.)
providing seed funding, d.) creating cross-department
budgeting mechanisms, and e.) generating strategic plans
that promote IDR.
Of importance, NIH Roadmap initiatives have established
a series of awards which facilitate interdisciplinary
research http://nihroadmap.nih.gov/interdisciplinary/
index.asp. These new awards provide funding for training
of scientists in interdisciplinary strategies, for creation of
interdisciplinary centers, and for conferences which cata-
lyze collaboration between the life and physical sciences.
In turn, AHC must respond by reconfiguring the reward
system (promotions, professional recognition) to accu-
rately value team-based research. Otherwise a new mani-
festation of conflict of interest will result.
This requires new strategies to appropriately identify team
members, to evaluate their contributions to the team, and
to adequately reward them for these contributions. While
detailed lists of recommendations [22] are beyond the
scope of this manuscript, selected budgetary policies are
reflective of the philosophy: a.) crediting a percentage of
indirect costs from all projects to support cross depart-
mental infrastructure for IDR, b.) providing seed money,
staff and space to support IDR, c.) creating a campus-wide
inventory of equipment to enhance sharing of across facil-
ities.
Conclusion
The "misalignments" described here derive from genuine
uncertainties about the best approaches to meeting the
research mission in AHC. They also emanate from a
reward system in AHC (and more broadly in universities)
which recognizes and rewards individual accomplish-
ments more than group performance. These conflicts are
not necessarily unhealthy, and can be described as balanc-
ing of competing priorities.
New initiatives outlined in the NIH Roadmap favor fund-
ing for programmatic, team-based research. Concurrently,
AHC must configure the reward system to appropriately
and accurately value contributions of team members.Publish with BioMed Central    and   every 
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Doing so will minimize conflict of interest, and will allow
AHC to more faithfully meet their mission.
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